Autolus Therapeutics (NASDAQ:AUTL) Receives “Buy” Rating from Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a research note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other brokerages also recently issued reports on AUTL. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. HC Wainwright started coverage on Autolus Therapeutics in a research report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Finally, Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Autolus Therapeutics Trading Down 7.4%

Shares of NASDAQ:AUTL traded down $0.10 during trading on Friday, reaching $1.20. The stock had a trading volume of 3,140,561 shares, compared to its average volume of 1,857,758. The firm’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.52. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70. The company has a market capitalization of $318.04 million, a P/E ratio of -1.45 and a beta of 1.95.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The firm had revenue of $24.29 million for the quarter, compared to the consensus estimate of $23.92 million. Equities research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marex Group plc purchased a new stake in shares of Autolus Therapeutics during the second quarter valued at $28,000. Independent Advisor Alliance acquired a new stake in Autolus Therapeutics during the 4th quarter worth about $28,000. SmartHarvest Portfolios LLC acquired a new stake in Autolus Therapeutics during the 4th quarter worth about $43,000. Caitong International Asset Management Co. Ltd purchased a new stake in Autolus Therapeutics during the 3rd quarter valued at about $46,000. Finally, R Squared Ltd grew its stake in Autolus Therapeutics by 40.1% during the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.